Krsnaa Diagnostics Limited has informed the Exchange that Board of Directors at its meeting held on May 12, 2025, recommended Final Dividend of 2.75 per equity share.
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.1 pts less than Nifty Microcap 250 and 7.0 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Krsnaa Diagnostics' Board approved audited financial results for Q4 and FY ended March 31, 2025, along with a final dividend of Rs 2.75 per share (55% of face value of Rs 5), subject to shareholder approval. Standalone revenue from operations grew 15.5% YoY to Rs 6,816.95 million in FY25, while profit after tax surged 41.4% to Rs 828.08 million. Consolidated revenue rose 15.7% to Rs 7,171.60 million with PAT up 36.5% to Rs 776.08 million. Operating cash flow improved sharply to Rs 893.79 million (standalone) from Rs 243.94 million last year. Auditors MSKA & Associates issued an unmodified opinion but flagged an emphasis of matter regarding income tax search proceedings with a total demand of Rs 513.86 million (Rs 102.77 million paid under protest), which the company is contesting.
Strong earnings growth and a meaningful dividend are positive signals for shareholders, though the unresolved Rs 513.86 million tax demand remains an overhang. EBITDA margin expansion and strong cash generation support the positive earnings picture, but investors should monitor the tax appeal outcome.